The Westin St. Francis lobby buzzed with its familiar January energy, a peculiar blend of jet lag, ambition, and the faint desperation of biotech CEOs clutching coffee cups like lifelines. This year’s JP Morgan Healthcare Conference arrived with a question hanging in the San Francisco fog: after years of what one executive called “nuclear winter,” were the capital markets finally thawing?
For BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook extends far beyond 2030. Yet despite all the strategic preparation, one key question will be answered in the coming months: can the clinical data live up to the high expectations surrounding BioNTech’s cancer strategy?
BioNTech SE